Sign In
Buy TLRY
Tilray Earnings Calls
| Release date | Jul 27, 2026 |
| EPS estimate | -$0.0100 |
| EPS actual | - |
| Revenue estimate | 250.481M |
| Revenue actual | - |
| Expected change | +/- 12.69% |
| Release date | Apr 01, 2026 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.240 |
| EPS Surprise | -71.43% |
| Revenue estimate | 201.35M |
| Revenue actual | 206.732M |
| Revenue Surprise | 2.67% |
| Release date | Jan 08, 2026 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.410 |
| EPS Surprise | -192.86% |
| Revenue estimate | 210.941M |
| Revenue actual | 217.507M |
| Revenue Surprise | 3.11% |
| Release date | Oct 09, 2025 |
| EPS estimate | -$0.266 |
| EPS actual | -$0.0042 |
| EPS Surprise | 98.43% |
| Revenue estimate | 204.549M |
| Revenue actual | 287.779M |
| Revenue Surprise | 40.69% |
Last 4 Quarters for Tilray
Below you can see how TLRY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Oct 09, 2025 |
| Price on release | $21.00 |
| EPS estimate | -$0.266 |
| EPS actual | -$0.0042 |
| EPS surprise | 98.43% |
| Date | Price |
|---|---|
| Oct 03, 2025 | $16.20 |
| Oct 06, 2025 | $15.80 |
| Oct 07, 2025 | $17.10 |
| Oct 08, 2025 | $17.20 |
| Oct 09, 2025 | $21.00 |
| Oct 10, 2025 | $17.20 |
| Oct 13, 2025 | $16.90 |
| Oct 14, 2025 | $16.00 |
| Oct 15, 2025 | $16.80 |
| 4 days before | 29.63% |
| 4 days after | -20.00% |
| On release day | -18.10% |
| Change in period | 3.70% |
| Release date | Jan 08, 2026 |
| Price on release | $9.13 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.410 |
| EPS surprise | -192.86% |
| Date | Price |
|---|---|
| Jan 02, 2026 | $9.72 |
| Jan 05, 2026 | $9.50 |
| Jan 06, 2026 | $9.26 |
| Jan 07, 2026 | $8.99 |
| Jan 08, 2026 | $9.13 |
| Jan 09, 2026 | $9.18 |
| Jan 12, 2026 | $9.30 |
| Jan 13, 2026 | $9.39 |
| Jan 14, 2026 | $9.90 |
| 4 days before | -6.07% |
| 4 days after | 8.43% |
| On release day | 0.548% |
| Change in period | 1.85% |
| Release date | Apr 01, 2026 |
| Price on release | $6.14 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.240 |
| EPS surprise | -71.43% |
| Date | Price |
|---|---|
| Mar 26, 2026 | $6.54 |
| Mar 27, 2026 | $6.32 |
| Mar 30, 2026 | $5.99 |
| Mar 31, 2026 | $6.47 |
| Apr 01, 2026 | $6.14 |
| Apr 02, 2026 | $6.55 |
| Apr 06, 2026 | $6.66 |
| Apr 07, 2026 | $6.46 |
| Apr 08, 2026 | $6.75 |
| 4 days before | -6.12% |
| 4 days after | 9.93% |
| On release day | 6.68% |
| Change in period | 3.21% |
| Release date | Jul 27, 2026 |
| Price on release | - |
| EPS estimate | -$0.0100 |
| EPS actual | - |
| Date | Price |
|---|---|
| May 28, 2026 | $5.65 |
| May 29, 2026 | $5.51 |
| Jun 01, 2026 | $5.49 |
| Jun 02, 2026 | $5.38 |
| Jun 03, 2026 | $5.11 |
Tilray Earnings Call Transcript Summary of Q1 2026
Tilray reported Q1 FY2026 results with record net revenue of $210M (up 5% YoY), GAAP net income of $1.5M, and improved adjusted EBITDA of $10.2M. Revenue growth was broad-based: Canadian adult-use and international cannabis grew double digits, distribution (CC Pharma) grew 9% driven by a stronger euro, wellness grew modestly, and beverage revenue was impacted by SKU rationalization and integration work. Management highlighted continued cost savings from Project 420 (approximately $25M realized toward a $33M target), ongoing SKU and facility rationalization, and improving retail relists for acquired beer brands (e.g., Shocktop, Montauk). Balance sheet strength improved: $265M cash, modest net debt (net debt to trailing-12mo adjusted EBITDA ~0.07x), $22.5M raised via ATM, $5M convertible notes exchanged for equity, and $7.7M debt reduction during the quarter. Management reaffirmed FY26 adjusted EBITDA guidance of $62–$72M and emphasized strategic optionality to capitalize on international medical cannabis expansion (EU/Germany/Portugal) and potential U.S. rescheduling opportunities. Key near-term execution priorities are continuing beverage integration, expanding EU medical distribution (CC Pharma), resolving permit/backlog issues (Portugal/Germany quotas), and driving margin recovery in cannabis and beverage segments.
